title: Renal complications of immune checkpoint blockade.
abstract: Immune checkpoint inhibitors have been approved for a variety of cancer species. Renal complications in use of these agents are not very common compared with other immune-related adverse events (irAE). However, it is crucial for physicians to recognize and manage renal manifestations of irAE. In this review, we will summarize the up-to-date knowledge of the clinical presentation, pathologic features, and management of renal irAE. In addition, we will discuss the safety of immune checkpoint inhibitors in patients with chronic kidney disease as well as in kidney transplant recipients.
authors.affiliation: Schuster Family Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Boston, Massachusetts; Renal Division, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address: nmurakami1@partners.org.
authors.forename: Naoka
authors.initials: N
authors.lastname: Murakami
authors.affiliation: Renal Division, Brigham and Women's Hospital, Boston, Massachusetts; Adult Survivorship Program, Dana Farber Cancer Institute, Boston, Massachusetts.
authors.forename: Shveta
authors.initials: S
authors.lastname: Motwani
authors.affiliation: Schuster Family Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Boston, Massachusetts; Renal Division, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address: lvriella@partners.org.
authors.forename: Leonardo V
authors.initials: LV
authors.lastname: Riella
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D056747:Immunomodulation / Q000187:drug effects*; D007674:Kidney Diseases / Q000139:chemically induced* / Q000276:immunology* / Q000517:prevention & control; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents
keywords: CTLA-4; Immune check point inhibitor; PD-1; acute kidney injury; chronic kidney injury; transplant